Mianserine Viatris (Mianserin Hydrochloride)

Mianserin works by blocking central α2‑adrenergic receptors and several serotonin receptors (5‑HT2, 5‑HT3) as well as histamine H1 receptors. This antagonism increases the release of norepinephrine and serotonin, enhancing neurotransmission that contributes to mood improvement.

The dosage of Mianserine Viatris is individualized by the prescribing clinician based on the patient’s clinical response, age, and tolerability. The prescriber determines the appropriate starting dose and any subsequent titration, following local prescribing guidelines.

Safety data for Mianserin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mianserin belongs to the tetracyclic antidepressant class, differing from selective serotonin reuptake inhibitors (SSRIs) in its receptor profile. While SSRIs primarily inhibit serotonin reuptake, Mianserin blocks α2‑adrenergic and multiple serotonin receptors, which can result in a distinct side‑effect profile, such as greater sedation and weight gain.

Mianserine Viatris should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Mianserine Viatris is taken orally, usually as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, as directed by the prescribing physician.

Serious risks include agranulocytosis or other severe blood disorders, seizures, cardiac arrhythmias, severe hypotension, and the emergence or worsening of suicidal thoughts. Patients should be monitored closely for any of these events, especially during treatment initiation or dose changes.

Mianserine Viatris is contraindicated in patients with known hypersensitivity to Mianserin or any excipients, those currently receiving monoamine oxidase inhibitors, and individuals with uncontrolled narrow‑angle glaucoma. Caution is also advised for patients with severe cardiovascular disease, epilepsy, or a history of blood dyscrasias.